Voyager Therapeutics (NASDAQ:VYGR) Share Price Passes Above 50 Day Moving Average – Here’s What Happened

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $3.34 and traded as high as $3.56. Voyager Therapeutics shares last traded at $3.54, with a volume of 406,199 shares trading hands.

Analyst Upgrades and Downgrades

Several research firms have issued reports on VYGR. HC Wainwright reiterated a “buy” rating on shares of Voyager Therapeutics in a research note on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Voyager Therapeutics in a research report on Monday, July 13th. Finally, Wall Street Zen downgraded Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $16.50.

Voyager Therapeutics Trading Up 2.3%

The company has a market cap of $218.13 million, a price-to-earnings ratio of -1.97 and a beta of 1.31. The stock has a 50 day moving average price of $3.34 and a two-hundred day moving average price of $3.68.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.08. The business had revenue of $3.17 million during the quarter, compared to the consensus estimate of $4.52 million. Voyager Therapeutics had a negative return on equity of 57.92% and a negative net margin of 312.63%. On average, equities analysts forecast that Voyager Therapeutics, Inc. will post -1.63 EPS for the current fiscal year.

Institutional Trading of Voyager Therapeutics

Large investors have recently made changes to their positions in the company. EcoR1 Capital LLC raised its position in shares of Voyager Therapeutics by 497.2% during the fourth quarter. EcoR1 Capital LLC now owns 4,002,847 shares of the company’s stock worth $15,731,000 after purchasing an additional 3,332,544 shares during the period. Altshuler Shaham Ltd bought a new position in shares of Voyager Therapeutics during the 4th quarter valued at about $801,000. Renaissance Technologies LLC grew its position in shares of Voyager Therapeutics by 95.0% in the 1st quarter. Renaissance Technologies LLC now owns 578,024 shares of the company’s stock valued at $2,231,000 after purchasing an additional 281,574 shares during the period. Seven Fleet Capital Management LP acquired a new position in shares of Voyager Therapeutics in the 1st quarter valued at approximately $445,000. Finally, Sei Investments Co. bought a new stake in Voyager Therapeutics during the 1st quarter worth approximately $112,000. Institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.